More biotechs join S&P300 index
Friday, 05 September, 2003
Market analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index.
Circadian Technologies, Genetic Technologies, Metabolic Pharmaceuticals and Norwood Abbey, along with retractable syringe specialist Unitract, will join the index from September 19.
Tim Eisenhauer, S&P's head of index services, said companies were selected to join the index on the basis if the free float of their shares, on their market capitalisation, and their liquidity over a six-month period.
The last healthcare firm to join the 300 was artificial heart maker Ventracor.
The S&P300's healthcare board also includes Agenix, Cellestis, Chemeq, Cochlear, CSL, IDT, Novogen, Peptech, ResMed and Sirtex.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
